News >

EU Panel Recommends Frontline Venetoclax/Obinutuzumab in CLL

Gina Columbus @ginacolumbusonc
Published: Friday, Jan 31, 2020

Michael Hallek, MD, director of the Department of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, and head, German CLL Study Group

Michael Hallek, MD

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the fixed-dose combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication